Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study

Annals of Hematology

Volumn 84, Issue 12, 2005, Pages 796-801

  Müller Beißenhirtz, Hannes ^a   Kasper, Christoph ^a   Nückel, Holger ^a   Dührsen, Ulrich ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Aggressive lymphoma; Gemcitabine; Phase II trial; Salvage therapy; Vinorelbine

Indexed keywords

CISPLATIN; CYTARABINE; DOXORUBICIN; GEMCITABINE; NAVELBINE; PREDNISONE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOMA; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INFECTION; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINBLASTINE;

EID: 29444450855     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1082-9     Document Type: Article

References (17)

1. Balzarotti M, Santoro A, Tondini C, Fornier M, Bonodonna G (1996) Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. Ann Oncol 7:970-972 9006750
2. Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Admas DJ, Rosner GL, Payne N, Davis P, Foster T, Moore JO, Rizzieri DA (2002) Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 20:2995-3000 10.1200/JCO.2002.08.166
3. Bernell P, Ohm L (1998) Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Haematol 101:203-204 10.1046/ j.1365-2141.1998.00667.x
4. Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D (2003) Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiple relapsed Hodgkin's and non Hodgkin's lymphoma. Br J Haematol 120:970-977 10.1046/j.1365-2141.2003.04226.x
5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castelino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCI sponsored International Working Group. J Clin Oncol 17:1244-1253 10561185 NCI
6. Coiffier B, Haioun C, Ketterer N, Engert H, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F (1998) Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932 9731049
7. Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR (1999) Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's Lymphoma. J Clin Oncol 17:3786-3792 10577850
8. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A (2000) Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure? J Clin Oncol 18:332-339 10637247
9. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
10. Nabhan C, Krett N, Gandhi V, Rosen S (2001) Gemcitabine in hematologic malignancies. Curr Opin Oncol 13:514-521 10.1097/00001622-200111000-00015
11. Peto R, Peto J (1972) Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc 135:185
12. Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F (2000) Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma 39:291-299 11342309
13. Savage DG, Rule SAJ, Tighe M, Garret TJ, Oster MW, Lee RT, Ruiz J, Heitjan D, Keohan ML, Flamm M, Johnson SA (2000) Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 11:595-597 10.1023/ A:1008307528519
14. Spencer A, Arthur C, Schwarer P (2002) Vinorelbine and gemcitabine with filgrastim (VGF) support shows significant activity against advanced lymphoma. Blood 100:781a (abstract # 3088) 10.1182/blood-2002-04-1148
15. Webb MS, Saltmann DL, Connors JM, Goldie JH (2002) A literature review of single agent treatment of multiple relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 43:975-982 10.1080/10428190290021632
16. Weidmann E, Kim SZ, Rost A, Schuppert H, Sepelt G, Hoelzer D, Mitrou PS (2002) Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1285-1289 10.1093/annonc/mdf189
17. Wong SF, Lindgren T, Hsu D, Tran G (2003) Low-dose gemcitabine plus cisplatin in previously treated, relapsed non-Hodgkin's lymphoma. Am J Hematol 73:298 10.1002/ajh.10349